The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Melas Kyriazi Theo since 2009.
This trader's CIK number is 1216078.
At the time of last reporting, Melas Kyriazi Theo was the Director of Codiak Biosciences, Inc.. (stock ticker symbol CDAK).
Also see all insider trading activities at Codiak Biosciences, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2009 | VRX | 15,000 | $292,785 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2020 | KLDO | 33,333 | $249,997 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | CDAK | 0 | $0 | 0 | $0 | 8,750 | $0 |
| 2020 | CDAK | 6,600 | $99,000 | 0 | $0 | 0 | $0 |
1. Valeant Pharmaceuticals International (VRX)
2. Kaleido Biosciences, Inc. (KLDO)
3. Codiak Biosciences, Inc. (CDAK)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2009-05-14 | VRX | Buy | 15,000 | 19.52 | 292,785 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2020-06-04 | KLDO | Buy | 33,333 | 7.50 | 249,997 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-02-16 | CDAK | Option Ex | 8,750 | .00 | 0 |
| 2020-10-13 | CDAK | Buy | 6,600 | 15.00 | 99,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Melas Kyriazi Theo (Director of Codiak Biosciences, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.